Pelthos Therapeutics (PTHS) Stock Sees Fair Value Cut As Analysts Rework Launch And Merger Risks
Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59
Pelthos Therapeutics Inc. Q3 2026 Earnings Call Summary
Pelthos (PTHS) Q3 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q3 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Pelthos Therapeutics Q3 2026 Earnings Call Transcript
Pelthos Therapeutics Q3 EPS $(2.04) Beats $(3.07) Estimate, Sales $15.395M Miss $17.605M Estimate
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
Pelthos and Castle Creek plan merger to target skin diseases
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
Pelthos Therapeutics Strikes Business Combination Agreement With Castle Creek Biosciences; Shareholders Of Castle Creek Biosciences To Receive 5.2M Common Shares Of Pelthos
Pelthos Therapeutics (PTHS) Stock Fair Value Falls After Analysts Cut Zelsuvmi Launch Estimates
Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos (PTHS) Q2 2026 Earnings Call Transcript
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
Pelthos Therapeutics Q2 Earnings Call Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.